Meihua Biological 梅花生物 (SSE 600873)
Meihua Holdings Group is a biotechnology company based out of LANGFANG. Meihua Holdings Group representatives, don’t miss out on opportunities to build relationships with members on LinkedIn. Claim your page, write a simple description, and share content to attract followers that can lead to new customers, brand fans, and future employees. Go here to get started: http://linkd.in/1DUpBvu
Profile
Meihua Biological (Meihua Holdings Group Co., Ltd.) is a global leader in large-scale bio-manufacturing, specializing in amino acids and synthetic biology. Headquartered in Langfang, Hebei, China, the company operates three major production bases in Tongliao, Wujiaqu, and Baicheng. It is listed on the Shanghai Stock Exchange (SSE 600873).
The company produces over 50 products across four core segments: animal nutrition amino acids (lysine, threonine, tryptophan), food flavor enhancers (MSG, xanthan gum), pharmaceutical-grade amino acids, and other bio-based products. It employs over 13,000 people and maintains an annual corn processing capacity of approximately 6 million tons.
Founded as a family business in the 1990s, Meihua transitioned from food trading to large-scale manufacturing. In July 2025, it completed the acquisition of Kyowa Hakko’s amino acid and HMO businesses, integrating them into its subsidiary, Plumino. In April 2026, it sold its Thai factory to Novonesis to focus on core operations. As of mid-2026, the company remains active, focusing on synthetic biology, AI-driven R&D, and global market expansion. In 2025, it reported annual revenue of 24.21 billion RMB.
Sources#
- Industry
- Alternative proteins, Food ingredients, Industrial chemistry
- Topics
- Amino acids & MSG fermentation, Sweeteners, polyols & starch derivatives, Synthetic biology platforms & biomanufacturing
- Role
- Research / RTO — “…domestic and international universities ( ) - research institutions ( ) - enterprises ( ) - Tongliao Meihua Bi…”
Bio-solutions it supplies 2
What they offer
Products: Plant Nutrition; Livestock Nutrition; Umami Agents; Food Ingredients; Colloids and Polysaccharides; Livestock Health; Plant-Based Protein and Others; L-Threonine; L-Lysine; Monosodium glutamate
Certifications: ISO 9001 Quality Management System Certification; ISO 22000 Food Safety Management System Certification; BRC Global Standard for Food Safety Certification; FAMI-QS EU Feed Safety Certification; IP Non-GMO Food Certification; Carbon Footprint Certification; Water Footprint Certification; Product Water Footprint Certificate
- Certifications (website)
- ISO 9001 Quality Management System Certification · ISO 22000 Food Safety Management System Certification · BRC Global Standard for Food Safety Certification · FAMI-QS EU Feed Safety Certification · IP Non-GMO Food Certification · Carbon Footprint Certification · Water Footprint Certification · Product Water Footprint Certificate
- Customers & partners
- Customers from 150 different countries · numerous prestigious domestic and international universities · research institutions · enterprises · Tongliao Meihua Biotechnology Co., Ltd. · Jilin Meihua Amino Acid Co., Ltd.
- Production sites
- Tongliao · Wujiaqu · Baicheng · Langfang, Hebei · Shanghai · Singapore · Tongliao, Inner Mongolia — MSG · Jilin Meihua Amino Acid Co., Ltd. — L-Lysine
- Products (website)
- Plant Nutrition · Livestock Nutrition · Umami Agents · Food Ingredients · Colloids and Polysaccharides · Livestock Health · Plant-Based Protein and Others · L-Threonine · L-Lysine · Monosodium glutamate · I+G · L-Glutamine
- R&D facilities
- Meihua Group R&D Center · R&D Center established in 2009 · State-of-the-art R&D laboratories · Pilot production workshops
Read from the company's own website: about · products · production · quality · rnd · leadership · contact · sustainability
Subsidiaries: 通辽梅花 (Tongliao Meihua) · 新疆梅花 (Xinjiang Meihua) · 吉林梅花 (Jilin Meihua)
News & status 6
- 2026-04 Latest status: In April 2026, the company sold its non-core assets, specifically the 100% equity of its Thailand factory, to Novonesis. ↗ ↗ ↗
- 2026-08-25 梅花生物Q2业绩环比大幅改善，医药氨基酸整合进入盈利阶段_腾讯新闻Meihua Biological梅花生物在2026年上半年实现收入与利润的环比改善，通过成本管控、医药氨基酸等高附加值产品布局以及产能与工艺升级提升韧性；二季度盈利显著回升并进入稳定盈利阶段，同时通过收购协和发酵等扩展至医药级氨基酸，正在向全球领先的生物发酵科技平台型企业转型。
- 2026-08-14 梅花生物上半年营收保持平稳 海外整合成效凸显_新浪财经_新浪网Meihua Bio (梅花生物)半年度营收基本持平，归母净利润小幅下降，但海外并购整合成效显著，旗下全资平台Plumino实现扭亏为盈并形成中美欧多区域协同的全球布局，国内产能持续扩大，赖氨酸等核心产品产能提升并优化产品结构。
- 2026-09-29 穆迪：上调梅花生物发行人评级至“Baa2”_中金在线财经号Meihua Biotech (MeiHua Holdings) has its issuer rating upgraded by Moody’s to Baa2 with a stable outlook, citing strong market position in amino acids, cost advantages, and solid liquidity, while noting earnings volatility from commodity cycles and that …
- 2026-09-17 营利双降 “味精大王”触及天花板？ - 财经绿动力Meihua Biological (梅花生物) is facing a profits-and-revenue slowdown as its main product, monosodium glutamate (味精), and other key products see price declines, though some specialty amino acids are expanding. The company needs strategic reforms—cost control, …
- 2026-08-14 梅花生物科技集团股份有限公司2026年半年度报告摘要_新浪财经_新浪网Meihua Biological (梅花生物)公布了其2026年半年度报告摘要，宣布自2026年1月1日起执行财政部的解释20号会计政策变更，旨在提高财务信息质量和可比性；此次变更对当前及可比期的财务状况和现金流影响不重大。公司计划于8月26日举行半年度业绩说明会。
- 2026-07-10 梅花生物启动小品类氨基酸升级改造项目-梅花集团Meihua Biological (梅花生物)宣布在通辽基地启动总投资3-5亿元的“小品类氨基酸升级改造与新产线扩建”项目，升级现有产线并新建多条高附加值医药氨基酸产线，以提升产能、转化效率和产品纯度，达到GMP标准并实现智能化生产。该举措旨在巩固其氨基酸主业龙头地位，提升产业链韧性与可持续发展。
Network: owners, partners, peers
Ownership & investors 3
| subsidiary | 通辽梅花 |
| subsidiary | 新疆梅花 |
| subsidiary | 吉林梅花 |
Partners & deals 1
| counterparty | 诺和新元 (Novonesis) (purchased non-core assets/Thailand factory) …In April 2026, the company sold its non-core assets, specifically the 100% equity of its Thailand factory, to Novonesis.… |
Similar companies
Cheil Jedang Indonesia · Fufeng Group · VEDAN Enterprise Corporation · Eppen Biotech · Hanling Group · CJ BIO Taste and Nutrition APAC · PT. Ajinomoto Indonesia · Angel yeast
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member